3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Motor Activity
32
Breast Neoplasms
21
Neoplasms
17
Prostatic Neoplasms
11
Obesity
8
Colorectal Neoplasms
6
Sarcopenia
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Polycystic Ovary Syndrome
4
Head and Neck Neoplasms
4
Signs and Symptoms
3
Multiple Myeloma
3
Lymphedema
3
Inflammation
3
Fatigue
3
Diabetes Mellitus, Type 2
3
Colonic Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Pharyngeal Neoplasms
2
Overweight
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Laryngeal Neoplasms
2
Insulin Resistance
2
Endometrial Neoplasms
2
Interventions
Cyclophosphamide
81
fludarabine phosphate
77
Peripheral Blood Stem Cell Transplantation
62
Mycophenolic Acid
55
Tacrolimus
54
Whole-Body Irradiation
52
Busulfan
51
Antilymphocyte Serum
45
Cyclosporine
41
fludarabine
36
Methotrexate
32
Filgrastim
32
Melphalan
30
Radiotherapy
25
Methylprednisolone
19
Cytarabine
17
Cord Blood Stem Cell Transplantation
17
Sirolimus
15
Azacitidine
15
Granulocyte Colony-Stimulating Factor
14
Alemtuzumab
14
thymoglobulin
13
Flow Cytometry
13
Etoposide
13
Cyclosporins
13
Specimen Handling
10
Biopsy
10
Thiotepa
9
Psychiatric Rehabilitation
9
Decitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myeloproliferative Disorders
×
Resistance Training
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled